Form 4: Forte Biosciences CEO Paul Wagner Reports Routine Stock Transactions

Forte Biosciences, Inc. CEO Paul A. Wagner filed a Form 4 detailing the exercise of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Summary

• Paul A. Wagner, CEO, Secretary, and Chair of the Board of Forte Biosciences, Inc. (FBRX), reported transactions on July 1, 2025.
• Wagner acquired 1,250 shares of Common Stock through the exercise of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 98 shares of Common Stock were disposed of at a price of $12.44 to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Wagner directly beneficially owns 80,940 shares of Common Stock.
• Additionally, Wagner directly holds 7,500 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
• RSUs vest at a rate of one-sixteenth (1/16th) on each Quarterly Vesting Date (January 1, April 1, July 1, and October 1) on or immediately following February 1, 2023, provided the reporting person remains a Service Provider.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports routine insider transactions (RSU vesting and tax-related sale) and does not contain information that would significantly alter the company's outlook or valuation.

Positives

• The RSU vesting indicates continued compensation and retention of a key executive, aligning management's interests with shareholders.
• The exercise price of $0 for the RSUs means these shares were granted as part of an equity incentive plan.

Negatives

• A portion of shares (98 shares) was sold, though this was for tax withholding and not a discretionary sale.

Future Outlook

No forward-looking statements or guidance regarding the company's financial performance or strategic direction are provided. The document only details future RSU vesting dates.

Management Comments

• No notable quotes or paraphrased statements from company management regarding strategy or performance are included. The document only identifies Paul A. Wagner's roles as CEO, Secretary, and Chair of the Board.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transactions, common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This Form 4 details a standard RSU vesting and tax-related sale, which is a common practice for executive compensation in publicly traded companies across various industries. No specific comparable companies, projects, or results are mentioned or implied.

Related Party Transactions

• The reported transactions are between an executive (Paul A. Wagner) and the company (Forte Biosciences, Inc.) as part of an equity incentive plan, which is a common form of related party transaction in corporate governance.

Stakeholder Impact

• Shareholders: The report provides transparency on executive compensation and shareholdings, which is generally positive for corporate governance. The sale of 98 shares for tax purposes is minimal and unlikely to have a material impact on share price.
• Employees: No direct impact on general employees is indicated.
• Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• Continued vesting of remaining Restricted Stock Units on subsequent Quarterly Vesting Dates (January 1, April 1, July 1, and October 1) as long as Paul A. Wagner remains a Service Provider.

Key Dates

Keywords

Forte Biosciences, FBRX, Paul A. Wagner, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transaction, Equity Incentive Plan, CEO, Corporate Governance